Thrombotargets Europe

Thrombotargets Europe is a clinical-stage biotechnology company focused on developing innovative therapies for the control of bleeding and wound healing. The company's core technology platform utilizes bio-active lipid-protein complexes to mimic the natural physiological processes of hemostasis. Its lead candidate, TT-173, is a topical hemostatic agent based on recombinant tissue factor that has demonstrated efficacy in reducing time to hemostasis in surgical settings. Thrombotargets aims to address unmet needs in surgical bleeding management and chronic wound care through its specialized pipeline of procoagulant and regenerative treatments.